Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
NCT03331250Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2018
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in angiosarcoma and epithelioid hemangioendothelioma (EHE), sponsored by Massachusetts General Hospital. Primary endpoint: Objective Response Rate at 2 years. Started Jan 2018; status: completed.
02
Drugs
eribulin
03
Conditions
angiosarcomaepithelioid hemangioendothelioma (EHE)
Beyond the preview
Go deeper on NCT03331250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331250.